01—Abstract
Summary
Summary of the 10-K filed March 25, 1994. Cited figures are marked; the original filing is the authoritative source.
Eli Lilly's 1993 10-K shows a year dominated by a large restructuring.
Worldwide sales rose 5% to $6.45 billiona, driven by a 6% rise in unit volume, with pharmaceuticals up about 7% to $4.7 billion (led by Axid and Prozac) and medical devices and diagnostics up about 4% to $1.3 billion. However, the company recorded $1.17 billion in restructuring and special charges (about $856 million after tax, or $2.91 per share), mainly from roughly 2,600 early retirements. Net income fell 32% to $480.2 million, or $1.63 per share, down from $2.41 in 1992.
Before the charges, earnings were largely stable, but the company's operating cost base was reset. The balance sheet remains sound. Cash and short-term investments totaled about $987 millionb, shareholders' equity was $4.57 billion, and long-term debt rose to $835 million after a $350 million issuance.
Dividends rose 10% to $2.42c per share, extending a 26-year streak of increases. However, the Moody's rating was cut to Aa1 from AAA in January 1994. Management also flagged rising pressure from U.S. managed care and Medicaid rebates ($156 million in 1993, up 44%), the expiration of key patents (Ceclor in the U.S. in 1992, Dobutrex in October 1993, with U.S. Dobutrex sales down about 75% in early 1994), and health-care reform.
Strategically, Lilly announced in January 1994 its intent to divest most of its Medical Devices and Diagnostics division, with six businesses to be spun off or publicly offered and three sold separately. The company also pursued a letter of intent to acquire Sphinx Pharmaceuticals, and it refocused R&D on five therapeutic areas. Investors should weigh the near-term earnings hit and expected cost savings against continued pricing pressure, patent expirations, and the pace of the MDD divestiture.
02—Key points
Key Highlights
- Net sales rose 5% to $6.45 billion, with unit volume up 6%, pharmaceuticals up about 7% to $4.7 billion, and medical devices and diagnostics up about 4% to $1.3 billion.
- Net income fell to $480.2 million ($1.63 per share) from $708.7 million ($2.41 per share) in 1992, because of $1.17 billion in restructuring and special charges ($2.91 per share after tax).
- About 2,600 employees are retiring under early-retirement programs, with a further 1,400 positions targeted for elimination over several years.
- Lilly announced intent to divest its Medical Devices and Diagnostics division, with six businesses to be spun off or publicly offered and three sold separately.
- Dividends rose 10% to $2.42 per share, the 26th consecutive annual increase, while Moody's cut the long-term debt rating to Aa1 from AAA in January 1994.
- Patent expirations weigh on results: Ceclor's U.S. patent expired in December 1992, and Dobutrex's expired in October 1993, with U.S. Dobutrex sales down about 75% in early 1994.
- Pricing pressure is increasing from managed care and Medicaid rebates, which reached $156 million in 1993 (up 44%), alongside uncertainty from U.S. health-care reform.
03—Questions
Frequently Asked Questions
Why did Lilly's net income fall so sharply in 1993?
Net income dropped 32% to $480.2 million, mainly because of $1.17 billion in pre-tax restructuring and special charges. These were largely driven by early-retirement programs (about $535 million), plant consolidations, and asset and intangible write-downs. Excluding these items, earnings were broadly stable with sales growth.
Is Lilly's dividend at risk after the restructuring?
Management raised the 1993 dividend to $2.42 per share, a 10% increase, and extended its streak of annual increases to 26 years. The board says future payments depend on earnings, financial condition, and requirements. The 1994 first-quarter dividend was declared at $0.625 per share, up 3.3%. Cash-based restructuring payments are expected to be funded from operations over an extended period.
What is the outlook for Lilly's key products and patent exposure?
Prozac and Axid drove 1993 growth, and Humulin, Humatrope, and Lorabid also contributed. Ceclor, the second-largest product, faces generic competition in the U.S. after its patent expired, though a key intermediate patent holds until December 1994. Dobutrex sales have fallen sharply after its patent expired. Humulin's patent runs to 2000, Prozac's to 2001, Axid's to 2002, and Lorabid's to 2004.
What is happening with the Medical Devices and Diagnostics division?
In January 1994, Lilly announced its intent to divest the MDD division. Six businesses (Advanced Cardiovascular Systems, Cardiac Pacemakers, Devices for Vascular Intervention, Heart Rhythm Technologies, IVAC, and Origin Medsystems) would go into a new holding company through a spin-off or public offering. Hybritech, Pacific Biotech, and Physio-Control would be sold separately. The final structure depends on tax, market, and bidder considerations.
What are the main legal and regulatory risks?
Lilly faces roughly 205 diethylstilbestrol suits and about 170 Prozac suits, plus patent suits involving Humulin and Humatrope. A federal grand jury in Baltimore is investigating FDA manufacturing compliance, and the company is also named in pharmacy pricing class actions. Management believes none of these will have a material adverse effect on its consolidated financial position. Health-care reform and foreign cost-control measures in Germany and Italy also add uncertainty to pricing and revenue.
04—Continue